FDA Approves New Treatment for Advanced Prostate Cancer

Introduction:

The U.S. Food and Drug Administration (FDA) has approved a new treatment for advanced prostate cancer. The treatment, called Lynparza (olaparib), is a targeted therapy that works by blocking a protein called PARP. PARP is involved in repairing DNA damage, and blocking PARP can help kill cancer cells that have accumulated DNA damage.

Who is eligible for Lynparza?

Lynparza is approved for men with advanced prostate cancer who have a mutation in the BRCA1 or BRCA2 gene. These genes are involved in DNA repair, and men with mutations in these genes are more likely to develop prostate cancer.

How does Lynparza work?

Lynparza works by blocking PARP, a protein that is involved in repairing DNA damage. When PARP is blocked, cancer cells that have accumulated DNA damage are more likely to die.

What are the side effects of Lynparza?

The most common side effects of Lynparza are nausea, vomiting, diarrhea, fatigue, and decreased appetite. Other side effects can include:

Bone marrow suppression
Anemia
Low white blood cell count
Low platelet count
Is Lynparza right for me?

If you have advanced prostate cancer and have a mutation in the BRCA1 or BRCA2 gene, you may be a candidate for Lynparza. Talk to your doctor to see if Lynparza is right for you.

Conclusion:

The FDA approval of Lynparza is a welcome development for men with advanced prostate cancer who have a mutation in the BRCA1 or BRCA2 gene. Lynparza is a targeted therapy that can help kill cancer cells that have accumulated DNA damage. If you are considering Lynparza, talk to your doctor to see if it is right for you.

For More Information Click here